ARQT — Arcutis Biotherapeutics, Inc.

Summary of Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Net Product Revenues: $127.5 million, an 84% increase year-over-year and a 29% sequential increase from Q3 2025.
• Full Year 2025 Net Product Revenues: $372.1 million, a 123% increase compared to 2024.
• Net Income for Q4 2025: $17.4 million, compared to a net loss of $10.8 million in Q4 2024.
• Cash Flow: Positive cash flow of $26.2 million in Q4 2025, with a cash and marketable securities balance of $221.3 million as of December 31, 2025.
• SG&A Expenses: Increased to $79 million in Q4 2025 (up 37% year-over-year) due to commercialization efforts for ZORYVE.
• R&D Expenses: Increased to $20.5 million in Q4 2025, reflecting ongoing clinical development activities.

2. Strategic Updates and Business Highlights

• ZORYVE Growth: ZORYVE, a topical roflumilast, is now the #1 branded nonsteroidal topical treatment for psoriasis, seborrheic dermatitis, and atopic dermatitis, with a market share of approximately 45%.
• New Approvals: FDA approvals for ZORYVE foam 0.3% for scalp and body psoriasis and ZORYVE cream 0.05% for atopic dermatitis in children aged 2-5.
• Clinical Development: Positive results from the Phase II INTEGUMENT-INFANT trial for ZORYVE cream in infants aged 3-24 months with atopic dermatitis. Plans for further label expansions are underway.
• Sales Force Expansion: A 20% increase in the dermatology sales force and the establishment of a dedicated team for primary care and pediatricians to enhance market penetration.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $480 million - $495 million, reflecting strong momentum for ZORYVE and ongoing investments in commercialization.
• Positive Cash Flow: Expected to maintain positive cash flow on a quarterly basis throughout 2026.
• Market Access: Continued improvement in access to ZORYVE, particularly with Medicare Part D plans, where approximately one-third of recipients now have coverage.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Anticipated revenue decline in Q1 2026 due to typical seasonal effects, including patient deductible resets and increased co-pay usage.
• Non-Preferred Drug Tier: ZORYVE's assignment to a non-preferred tier in Medicare may temper demand due to higher out-of-pocket costs for patients.
• Competitive Pressures: The market dynamics with competitors like Incyte, which may necessitate pricing adjustments to improve access, could impact ZORYVE's market position.

5. Notable Q&A Insights

• Market Access Strategy: Management expressed confidence in ZORYVE's access strategy, noting over 80% access among commercial insurance patients and significant improvements in Medicaid and Medicare coverage.
• Sales Force Effectiveness: The expansion of the sales force is expected to enhance engagement with mid-decile prescribers, which could drive further adoption of ZORYVE.
• Pediatric Market Potential: Strong initial uptake of ZORYVE cream for children aged 2-5, with positive feedback from healthcare providers regarding its safety and efficacy.
• Future Commercial Opportunities: Management indicated that while they are focused on ZORYVE, they are also exploring additional development-stage assets for future growth, rather than acquiring commercial-stage products that could distract from their core strategy.

Overall, Arcutis demonstrated strong financial performance and strategic growth initiatives in Q4 2025, positioning itself for continued success in 2026 despite some anticipated challenges.